The class III receptor tyrosine kinase FMS-like tyrosine kinase 3 (FLT3) regulates normal hematopoiesis and immunological functions. Nonetheless, constitutively active mutant FLT3 (FLT3-ITD) causally contributes to transformation and is associated with poor prognosis of acute myeloid leukemia (AML) patients. Histone deacetylase inhibitors (HDACi) can counteract deregulated gene expression profiles and decrease oncoprotein stability, which renders them candidate drugs for AML treatment. However, these drugs have pleiotropic effects and it is often unclear how they correct oncogenic transcriptomes and proteomes. We report here that treatment of AML cells with the HDACi LBH589 induces the ubiquitin-conjugating enzyme UBCH8 and degradation of FLT3-ITD. Gain-and loss-offunction approaches show that UBCH8 and the ubiquitin-ligase SIAH1 physically interact with and target FLT3-ITD for proteasomal degradation. These ubiquitinylating enzymes though have a significantly lesser effect on wild-type FLT3. Furthermore, physiological and pharmacological stimulation of FLT3 phosphorylation, inhibition of FLT3-ITD autophosphorylation and analysis of kinase-inactive FLT3-ITD revealed that tyrosine phosphorylation determines degradation of FLT3 and FLT3-ITD by the proteasome. These results provide novel insights into antileukemic activities of HDACi and position UBCH8, which have been implicated primarily in processes in the nucleus, as a previously unrecognized important modulator of FLT3-ITD stability and leukemic cell survival.
Introduction
Class III receptor tyrosine kinases (RTKs) control the development of hematopoietic progenitor cells. 1, 2 Wild-type FMS-like tyrosine kinase 3 (FLT3) has been shown to be highly expressed in several hematopoietic malignancies including 70-100% cases of acute myeloid leukemia (AML). [3] [4] [5] [6] Overexpression of FLT3 promotes receptor autophosphorylation linked to leukemic transformation. 4, 5, 7 Activating mutations of FLT3 occur in up to 30% of patients having AML. The most common FLT3 mutation in AML represents an internal tandem duplication (ITD) in the juxtamembrane region. 8 This FLT3-ITD mutation has also been found in smaller fractions of chronic myeloid leukemia, myelodysplasia as well as B-and T-cell acute lymphoblastic leukemia. [9] [10] [11] FLT3-ITD exists partially in an immature, underglycosylated, constitutively phosphorylated form. Aberrant intracellular localization and activity of FLT3-ITD generate oncogenic phosphorylation patterns. [12] [13] [14] [15] [16] [17] Large-scale analyses of AML patients revealed FLT3-ITD as an independent prognostic marker for disease relapse and poor prognosis. 9, 18, 19 Point mutations in the tyrosine kinase domain (TKD) are a second type of FLT3 mutation found in AML, acute lymphoblastic leukemia and myelodysplasia. 7, 20 Although both types of mutations result in constitutive receptor activation, they are associated with distinct signaling properties and disease phenotypes. In contrast to FLT3-ITD, the prognostic impact of TKD mutations of FLT3 is discussed rather controversially. 14, [21] [22] [23] [24] Several studies with murine models show the transforming potential of mutant FLT3. As single mutation, FLT3-ITD is sufficient to induce a myeloproliferative phenotype. Moreover, similar to FLT3-TKD, FLT3-ITD causes also lymphoid disease in transgenic or bone-marrow-transplanted mice. 6, 21, [25] [26] [27] These findings link FLT3-ITD to the pathogenesis of myeloid and lymphoid leukemias. Consistent with the development of AML being a consequence of multiple genetic alterations, FLT3-ITD cooperates with further lesions generating leukemogenesis, manifested by development of acute leukemia with short disease latency in vivo. [28] [29] [30] [31] For example, FLT3-ITD and the chromosomal translocation t(15;17) encoding PML/RARa are found in combination in approximately 40% of patients with t(15;17) AML. 32 The fact that expression of FLT3-ITD induces murine acute promyelocytic leukemia-like disease in PML/RARa transgenic mice corroborates their oncogenic cooperation. 33, 34 Such observations argue for a critical role for mutated FLT3 in the pathogenesis of acute leukemia. Consequently, detailed analyses of the functions, properties, and turnover of FLT3 and its mutants are warranted.
Because targeted deletion of FLT3 or FLT3-ligand (FL) does not compromise the viability of mice, intervention with deregulated FLT3 functions appears as a potential treatment option for AML. [35] [36] [37] The proteasome, a multiprotease complex, limits the stability of activated FLT3 and mutant FLT3-ITD. [38] [39] [40] [41] Therefore, proteasomal degradation provides a pharmacological avenue for interference with aberrant FLT3. Targeting of a protein to the proteasome requires polyubiquitinylation carried out by the hierarchical action of ubiquitin-activating enzymes (E1s), ubiquitin conjugases (E2s) and ubiquitin ligases (E3s) conferring substrate specificity. 42, 43 A complex containing the E3 ubiquitin ligase CBL contributes to FL-induced ubiquitinylation and degradation of ectopically expressed human wild-type FLT3 in COS7 and 32D cells. 38 Enzymes and molecular mechanisms regulating FLT3-ITD expression and stabilities are defined sparsely.
Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer drugs, which affect gene expression and signaling by inducing acetylation of histones and nonhistone proteins. 42, [44] [45] [46] [47] The HDACi NVP-LBH589 (LBH589) and NVP-LAQ-824 target FLT3 and FLT3-ITD for degradation. Acetylation-dependent HSP90 chaperone complex disassembly has been proposed as a mechanism underlying this process. 39, 40, 48, 49 Nevertheless, these compounds may equally destabilize these kinases independent of HSP90. Moreover, it is unclear which E2 and E3 enzymes catalyze the degradation of mutant FLT3 in AML cells treated with HDACi.
We have previously shown that HDACi induce ubiquitinylation and proteasomal degradation of the nuclear leukemia fusion proteins AML1/ETO and PML/RARa. Upregulation of the E2 ubiquitin conjugase UBCH8 acting in concert with the E3 ubiquitin ligase SIAH1 accounts for this process. 50 These and other reports suggest that HDACi can induce degradation of (proto-)oncoproteins by modulating the expression of enzymes catalyzing polyubiquitinylation.
42,51-53 Therefore, we analyzed whether HDACi alter the expression of UBCH8 and SIAH1 in AML cells. We further determined if these enzymes catalyze degradation of FLT3-ITD by the ubiquitin-proteasome system (UPS). In addition, we assessed the role of tyrosine phosphorylation for basal and HDACi-induced turnover of FLT3 and FLT3-ITD in AML cells and in a heterologous expression system. Our findings emphasize a critical role for UBCH8 in basal and HDACi-mediated turnover of FLT3-ITD. Induction of UBCH8 by HDACi and subsequently enhanced proteasomal degradation of its targets might contribute to antileukemic effects of HDACi.
Materials and methods

Drugs and chemicals
NVP-LBH589 (LBH589) was a gift from Novartis; FLT3-specific inhibitor bis(1H-indol-2-yl)methanones cpd. 102 (cpd.102) has been already described, 54 recombinant human FLT3 ligand (FL) was purchased from PeproTech GmbH (Hamburg, Germany); the pan-caspase inhibitor Z-VAD-FMK (Z-VAD) from Bachem (Weil am Rhein, Germany); Amaxa Nucleofector kit from Lonza (Kö ln, Germany); Lipofectamine 2000 from Invitrogen (Karlsruhe, Germany); the proteasome inhibitor Z-Leu-LeuLeu-al (MG132), N-ethyl-maleimide, sodium orthovanadate (Na 3 VO 4 ), cycloheximide (CHX) and polyethylenimine were purchased from Sigma-Aldrich (Steinheim, Germany).
Cell lines
HEK293T and HeLa cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 1% penicillin/streptamycin and 2% L-glutamine. MV4-11 (expressing FLT3 with ITD, FLT3-ITD) and RS4-11 (expressing wild-type FLT3) cell lines were grown in Rosewell Park Memorial Institute (RPMI) medium containing same additives. All cell lines were cultured at 37 1C in a 5% CO 2 atmosphere.
Plasmids, siRNAs, transfection assays and FACS analyses
The following plasmids have been described previously: UBCH8-V5; 51 50 Fluorescence-activated cell sorting (FACS) analyses for detection of apoptotic cell death were performed as described. 50 Western blot, immunoprecipitation, GST pull-down and antibodies
Cells were collected and lysed in NET-N buffer (150 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl (pH 7.8), 0.5% Nonidet P-40 (NP-40), 1 mM phenylmethylsulfonyl fluoride, 0.5 mg/ml leupeptin and 0.5 mg/ml pepstatin) followed by mild sonification on ice. Protein lysate (50-100 mg) was boiled in Laemmli buffer and separated on SDS-polyacrylamide gel electrophoresis for western blotting with specific antibodies. All lysates were assessed by Bradford assay for protein concentrations. Tubulin served as loading control for all western blots. For immunoprecipitations, HEK293T cells were transfected with a total of 10 mg DNA per 5 Â 10 6 cells and lysates were prepared 48 h later. MG132 (1-2 mM) was added 16 h before cell lysis to prevent RTK degradation. Cell lysis and precipitations were performed in NET-N buffer (additionally supplemented with N-ethyl-maleimide 10 mM, NaF 1 mM, Na 3 OV 4 1 mM). For precipitation, 1 mg of antibody and 10 ml of protein G Sepharose beads (GE Healthcare, Mü nchen, Germany) were added to 500 mg of lysate protein. The immunoprecipitation volume was adjusted to a total volume of 600 ml with NET-N. Precipitation was performed under continuous rotation for 16 h at 4 1C. Beads were washed and bound proteins were eluted with Laemmli buffer and analyzed by western blotting. As a control, immunoprecipitations were performed in parallel with normal IgG (pre, preimmune serum) from the same hosts. For pull-down experiments, UBCH8 and SIAH1 were expressed as glutathione S-transferase (GST) fusion proteins as described. 50 FLT3-ITD was expressed in vitro in a cell-free reticulocyte lysate system (Promega, Mannheim, Germany). Pull-down experiments were performed with 5 mg heterologously expressed GST-UBCH8 or GST-SIAH1 (GST as control) and 10 ml of reticulocyte lysate. GST pull-downs experiments were performed as stated for immunoprecipitation studies. Preparation of detergent-soluble and -insoluble fractions was performed as described. 40 Cell extracts from different fractions were boiled in Laemmli buffer and analyzed by western blot. Densitometric analyses of protein bands in western blots were performed with Adobe Photoshop_CS4. To determine the relative protein band density in each sample, we set the average gray value of the specific protein band in relation to the tubulin signal. Relative protein levels were calculated by normalization against mock sample from the same experiment.
Antibodies used in western blot or immunoprecipitation experiments were purchased from Santa Cruz Biotechnology 
Results
HDACi selectively target FLT3-ITD for degradation
Recent studies showed that the HDACi LAQ-824 and LBH589 attenuated FLT3 and FLT3-ITD in AML cell lines.
39, 40 First, we investigated whether HDACi affect RTK levels in such cells to the same extent. We found that LBH589 and valproic acid reduced FLT3-ITD time dependently in MV4-11 cells. In contrast, the same treatment conditions decreased FLT3 levels significantly lesser in RS4-11 cells (Figure 1a ; data not shown).
We and others previously showed that HDACi induce the E2 enzyme UBCH8, which in conjunction with the ubiquitin E3-ligase SIAH1, evokes proteasomal degradation of nuclear proteins involved in tumorigenesis. [50] [51] [52] 58 We found that LBH589 induced UBCH8 in MV4-11 cells in a time-dependent manner. Remarkably, increased expression of UBCH8 correlated inversely with the levels of FLT3-ITD. In contrast to UBCH8, SIAH1 protein levels were unaffected by LBH589 (Figure 1b ). Analyzing the mRNA transcript levels of FLT3-ITD by quantitative real-time PCR analysis revealed that LBH589 did not decrease FLT3-ITD mRNA expression (data not shown), which suggests that enhanced UBCH8 levels promote the turnover of FLT3-ITD.
Because HDACi potently induce apoptosis of leukemic cells, we next analyzed the possibility of caspase-mediated proteolysis of FLT3-ITD. MV4-11 cells were treated with LBH589 in the presence of the cell-permeable pan-caspase inhibitor Z-VAD-FMK. Incubation of MV4-11 cells with LBH589 for 24 h strongly decreased FLT3-ITD levels. This process could be partially restored by Z-VAD-FMK, indicating that degradation of FLT3-ITD is partly mediated by a caspase-dependent process. Attenuation of FLT3-ITD also correlated with the processing of its chaperone HSP90 and of caspase 3 ( Figure 1c) .
Fluorescence-activated cell sorting analysis quantifying sub-G 1 DNA content revealed that co-incubation with Z-VAD-FMK completely blocked LBH589-induced apoptosis in MV4-11 cells. Hence, caspase-dependent cell death is responsible for the for the growth inhibitory effect of LBH589 (Figure 1c, right) . Because even relatively high concentrations, up to 50 mM Z-VAD-FMK, could only partially abolish the LBH589-induced decrease of FLT3-ITD levels (data not shown), a caspaseindependent pathway must also contribute to the loss of FLT3-ITD in LBH589-treated MV4-11 cells. An obvious candidate is proteasomal degradation.
To test the putative role of the proteasomal pathway for FLT3-ITD degradation, we co-incubated MV4-11 cells with LBH589 and the proteasomal inhibitor MG132 (Figure 1d ). Cells were pretreated with LBH589 for 16 h, which evoked FLT3-ITD degradation and upregulation of UBCH8 (Figure 1b) . Afterwards, MG132 was added and cells were incubated with CHX to prevent new protein synthesis. Exposure to MG132 prolonged the half-life of FLT3-ITD, which indicates basal degradation of this RTK through the proteasome. Furthermore, LBH589 accelerated the turnover of FLT3-ITD, whereas MG132 attenuated LBH589-induced destabilization of FLT3-ITD (Figure 1d ; Supplementary Figure S1 ). This experiment confirmed that the proteasome mediates the basal turnover of this oncoprotein and that its proteasomal degradation is accelerated by LBH589.
Our study data show that the HDACi LBH589 evokes apoptosis and induction of UBCH8 correlating with degradation of FLT3-ITD in AML cells. Both, proteasome-and caspasedependent mechanisms account for this proteolytic process.
UBCH8 mediates degradation of mutant FLT3 in AML cells
These observations prompted us to test whether increased UBCH8 expression triggered proteasomal degradation of 
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M Buchwald et al FLT3-ITD. To address the role of UBCH8, which operates in conjunction with the E3 ligase SIAH1, we ectopically expressed these proteins in MV4-11 cells. To exclude putative apoptotic degradation of FLT3-ITD, we also added Z-VAD-FMK. Indeed, enhanced levels of UBCH8 and SIAH1 markedly destabilized FLT3-ITD (Figure 2a ). To further investigate the role of UBCH8 in the LBH589-induced FLT3-ITD degradation, we lowered endogenous UBCH8 levels with siRNAs that were previously shown to target this E2 ubiquitin conjugase efficiently. 50, 51 Our transfection protocol allowed at least 50% reduction of UBCH8 at the protein and mRNA levels (Figure 2b ; data not shown) and this sufficed to increase FLT3-ITD levels by 40% in MV4-11 cells (Figure 2c, lane 1 versus lane 3) . Transfection of UBCH8 siRNAs also reduced the LBH589-induced degradation of FLT3-ITD. FLT3-ITD showed a more than threefold enhanced stability in cells transfected with UBCH8 siRNAs compared with
Together with the approximately 50% reduction of UBCH8, we found that LBH589-induced apoptosis was decreased by 50%. These data suggest a causal role for UBCH8-mediated degradation of FLT3-ITD and apoptosis induction by HDACi. To analyze the relevance of FLT3-ITD activity for cell survival, we incubated MV4-11 cells with the FLT3-ITD-specific inhibitor cpd.102, which has previously been shown to inhibit FLT3-ITD autophosphorylation and receptor signaling efficiently in these cells. 54, 59 Treatment with cpd.102 inhibited FLT3-ITD phosphorylation at Y591 (pY591), a site indicating receptor activation, 60 and this agent induced apoptosis to a similar extent as LBH589 did. Hence, both FLT3-ITD inactivation and elimination are linked to leukemia cell death confirming oncogene addiction. Co-incubation of MV4-11 cells with both substances resulted in complete cleavage of caspase 3 and even enhanced apoptosis (Figure 2d) .
These data emphasize the role of UBCH8 for the basal stability and LBH589-evoked proteasomal degradation of mutant FLT3 and indicate that FLT3-ITD and UBCH8 critically regulate cell survival and HDACi-mediated apoptosis in MV4-11 AML cells.
UBCH8 preferentially induces proteasomal degradation of FLT3-ITD
To further analyze the mechanism of UBCH8-mediated degradation of FLT3-ITD, we ectopically expressed FLT3-ITD together with UBCH8 in HEK293T cells. Because HEK293T cells do not undergo apoptosis, or any other form of cell death, when UBCH8 or SIAH proteins are overexpressed, 51 ,61 apoptotic processes are unlikely to contribute to FLT3-ITD degradation in this setting. As shown in Figure 3a , co-expression of UBCH8 strongly decreased the levels of FLT3-ITD.
Next, we analyzed whether this effect of UBCH8 depends on the proteasome. When we treated UBCH8-and FLT3-ITDexpressing HEK293T cells with the proteasomal inhibitor MG132, we noted accumulation of basal FLT3-ITD levels and that the UBCH8-induced turnover of FLT3-ITD was blocked. Polyubiquitinylated FLT3-ITD was shown to accumulate in the detergent-insoluble lysate fraction. 40 Therefore, we probed cell fractions representing detergent-insoluble proteins from HEK293T cells co-expressing UBCH8 and FLT3-ITD for FLT3. This analysis revealed a smear of species with higher molecular mass, which most likely represent polyubiquitinylated receptors (Figure 3a) . These findings indicate that UBCH8 targets FLT3-ITD to the UPS.
Considering the differential sensitivities of FLT3 and FLT3-ITD to HDACi in AML cells, we investigated whether these kinases show divergent susceptibility to UBCH8 in our heterologous expression system. Indeed, FLT3-ITD was effectively degraded upon co-expression of UBCH8 in HEK293T cells, whereas FLT3 was hardly affected (Figure 3b) . We further noticed that despite comparable efficiencies of transfection (analyzed with fluorescence microscopy and western blot for co-expressed GFP), FLT3-ITD was expressed in HEK293T cells at lower levels than FLT3. Most likely, this reflected a higher turnover rate, which is consistent with a basal expression of UBCH8 in these cells (Figure 3b ; data not shown). 50, 51 Prompted by these considerable differences in the sensitivity of FLT3 and its ITD mutant to UBCH8, we tested whether these kinases associate differentially with UBCH8. FLT3 or FLT3-ITD was co-expressed with UBCH8 in HEK293T cells. Probing of UBCH8 immunoprecipitates with an FLT3-specific antibody detected significantly more FLT3-ITD than FLT3 in immunocomplexes with UBCH8 (Figure 3c ). In agreement with this finding, in situ immunofluorescence analysis showed that UBCH8 exhibited an overlapping localization with FLT3-ITD. Apparently, there was lesser colocalization detectable with the cell-surface-bound fraction of the wild-type receptor (Supplementary Figure S3) .
Taken together, these results show that UBCH8 induces FLT3-ITD degradation by the UPS in HEK293T cells. Remarkably, UBCH8 associates with and degrades mutant FLT3-ITD more strongly than wild-type FLT3.
Tyrosine phosphorylation governs UBCH8-triggered degradation of FLT3-ITD
MV4-11 cells expressing FLT3-ITD were found to be more sensitive to HDACi-mediated induction of apoptosis than RS4-11 cells expressing FLT3.
39, 62 We could confirm a higher sensitivity of MV4-11 cells to HDACi treatment. Cleavage of HSP90 and induction of apoptosis, indicated by processing of the precursor caspase 3 into the cleaved active form, could only be detected in MV4-11 cells. Surprisingly, UBCH8 protein was only induced in MV4-11 cells but not in RS4-11 cells, which express appreciable levels of this enzyme independent of HDAC inhibition (Figure 4a) . Moreover, real-time PCR analyses revealed that RS4-11 cells have an approximately 10-fold higher number of transcripts coding for UBCH8 than MV4-11 cells (data not shown). Analysis of UBCH8 levels in further human 
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M Buchwald et al AML cell lines with wild-type FLT3 expression (RS4-11, THP-1 and EOL-1) revealed higher UBCH8 levels in these cell lines compared with MV4-11 cells. In contrast, SIAH1 was expressed at equal levels in these cells (Figure 4b ). On the basis of these observations and the fact that UBCH8 preferentially degraded constitutively active FLT3-ITD, we investigated whether tyrosine phosphorylation regulates this process. To enhance phosphorylation of FLT3, we treated HEK293T cells expressing FLT3 and UBCH8 with doses of the general protein-tyrosine phosphatase inhibitor orthovanadate not impairing cell viability. 57 Orthovanadate caused equal phosphorylation of FLT3 and FLT3-ITD at pY591 (Supplementary Figure S2 ). Consistent with our previous data, FLT3 protein level was nearly unaffected by exogenously expressed UBCH8. However, induction of FLT3 phosphorylation by orthovanadate caused its efficient degradation in the presence of UBCH8 (Figure 4c) . Moreover, activation of FLT3 with its physiological ligand FL induced receptor autophosphorylation (Supplementary Figure S2 ) and UBCH8-mediated degradation to an extent similar to that observed for mutant FLT3 (compare Figures 3a, b  and 4c ).
To further substantiate the role of tyrosine phosphorylation for FLT3 degradation, we incubated HEK293T cells expressing UBCH8 and FLT3-ITD with its specific inhibitor cpd.102. In addition, we analyzed whether UBCH8 induced degradation of a catalytically inactive FLT3-ITD mutant harboring a lysine to alanine exchange in its catalytic cleft (ITD-KA). 13 Inhibition of tyrosine phosphorylation, with this chemical inhibitor or by mutagenesis, rendered FLT3-ITD insensitive to UBCH8-mediated degradation (Figures 4d and e) . Of note, the effects of cpd.102 and the ITD-KA mutation on the UBCH8-mediated depletion of FLT3-ITD were as prominent as those achieved with an inhibitor of the proteasome (Figure 3a) . Accordingly, inhibition of FLT3-ITD phosphorylation by cpd.102 stabilized its protein level in MV4-11 cells (Figure 2d, lane 3) .
These data suggest that degradation of FLT3 and FLT3-ITD through UBCH8 depends on tyrosine phosphorylation.
SIAH E3 ubiquitin ligases targets FLT3-ITD for proteasomal degradation
It is known that UBCH8 and the RING E3 ligase SIAH1 functionally cooperate in various cell types. 50, 63, 64 To test their potential interaction in the degradation of FLT3 and FLT3-ITD, we expressed these kinases together with the E3 ligase SIAH1 in HEK293T cells. Similar to overexpression of UBCH8, increasing amounts of SIAH1 lowered FLT3-ITD levels far more strongly than those of FLT3 (Figure 5a ). In the latter case, a minor pool of autoactivated FLT3 (weak activation is caused by overexpression) was the primary target of degradation (Figure 5a) .
We further investigated whether the increased degradation of FLT3-ITD on SIAH1 co-expression is reflected by binding to SIAH1. SIAH1 was precipitated with a specific antibody and immunocomplexes from HEK293T cell lysates were analyzed for the presence of FLT3. This experiment showed that a larger fraction of FLT3-ITD than FLT3 was found in precipitates formed under physiological conditions with an SIAH1 antibody (Figure 5b ). This was similar to the complex formation detected between UBCH8 and FLT3-ITD (Figure 3c ).
To address whether UBCH8 or SIAH1 is the direct binding partner of FLT3-ITD, we performed in vitro binding assays. FLT3-ITD was expressed in a cell-free system and pull-down experiments were performed with GST fusions of UBCH8 or SIAH1. FLT3-ITD preferentially bound to SIAH1. Although this agrees with RING E3 ligase-mediated substrate recognition, a very minor binding of UBCH8 to FLT3-ITD was also detectable (Figure 5c ).
Finally, we tested whether overexpression of further ubiquitinligases, such as TRIAD1, RLIM or MDM2, had an effect on FLT3-ITD levels in HEK293T cells. However, these E3 enzymes had no effect on FLT3-ITD stability (data not shown). CBL, an SH2 domain-containing multiadapter protein with RING finger E3 ligase activity, regulates RTK endocytosis and sorting to the lysosomal degradation machinery. [65] [66] [67] [68] [69] Because CBL targets wild-type FLT3 for ubiquitinylation, 38 we investigated how expression of this ubiquitin ligase, in comparison to SIAH1 and the related SIAH2, 55 affects stability of the FLT3-ITD mutant in HEK293T cells. We found that expression of SIAH proteins resulted in complete loss of FLT3-ITD, whereas CBL overexpression selectively reduced the level of the higher migrating band of FLT3-ITD (Figure 5c ). This band corresponds to the mature, glycosylated receptor. 13 These data may indicate a specificity of CBL for mature FLT3 at the cell-surface and that SIAH proteins potently target FLT3-ITD.
Discussion
Histone deacetylase inhibitors are promising anticancer drugs for the treatment of leukemia. 70 Detailed analyses of specific Proteasomal degradation of FLT3-ITD catalyzed by UBCH8 M Buchwald et al and pleiotropic actions of these compounds are required to predict and ensure therapeutic benefits. Particularly less information is available on enzymes and molecular pathways participating in HDACi-induced proteasomal degradation.
Here, we show with inhibitor studies, ectopic expression, and siRNA approaches that HDACi treatment leads to degradation of oncogenic FLT3-ITD through the HDACi-inducible E2 ubiquitin conjugase UBCH8 and the E3 ligase SIAH1 in AML cells. Congruent with these findings, we and others already showed that a specific cooperation of SIAH1 with UBCH8 induces protein degradation. 50, 63, 64 In addition, we previously discovered that the leukemia-associated transcription factors AML1/ ETO and PML/RARa, which are often found in conjunction with mutated tyrosine kinases, 60 are also degraded by UBCH8 and SIAH1. 50 Thus, targeting of both, nuclear leukemia fusion proteins and oncogenic RTK signaling, by induction of UBCH8, may contribute to the frequently observed antileukemic actions of HDACi. 42, [44] [45] [46] 71 Remarkably, depletion of UBCH8 by siRNA reduces the sensitivity of MV4-11 cells toward LBH589-mediated induction of apoptosis, emphasizing the role of UBCH8 for the HDACi treatment of AML. 50 In line with previous reports, revealing FLT3-ITD as important factor for cell proliferation and survival of AML cells in vitro and in murine models, 7, [72] [73] [74] we could show that specific kinase inhibition of FLT3-ITD not only induces apoptosis in AML cells per se, but also renders them more sensitive to HDACi-induced cell death. These data confirm that phosphorylation of FLT3-ITD and subsequent oncogenic signaling ensure cell survival and that this oncoprotein is a valid target for leukemia treatment. 59, [72] [73] [74] [75] In agreement with these findings, combinatorial treatment of AML cells with HDACi and FLT3 inhibitor results in enhanced caspase activation and strong induction of apoptosis. Thus, caspases can function in a feedforward mechanism, which promotes degradation of FLT3-ITD and compensates reduced proteasomal degradation of inactivated receptor. Because targeting of FLT3-ITD stability appears as a crucial effect of HDACi, combining HDACi and FLT3-specific kinase inhibitors may gives beneficial effects in vivo. Such a strategy impairs both expression and activity of the oncoprotein.
It is generally accepted that RING E3 ligases selectively mediate the transfer of E2-bound ubiquitin to a substrate. Previous observations and our biochemical data presented here show that SIAH1 can function as E3 for UBCH8 in the HDACi-induced depletion of FLT3-ITD in AML cells. 50, 63, 64 In contrast to mutant FLT3, wild-type FLT3 remains stable in the presence of already high levels of basal UBCH8 in AML cells. According to our data, stimuli inducing phosphorylation of FLT3 and constitutive autophosphorylation of FLT3-ITD direct them for UBCH8/SIAH1-mediated degradation. Consistently, inhibition of FLT3-ITD phosphorylation prevents proteasomal degradation, which argues for preferential elimination of the active kinase. Because limited expression of UBCH8 might be a prerequisite for stable levels of FLT3-ITD and other (onco-) proteins, [50] [51] [52] it is tempting to speculate that deregulation of this E2 might be a step in cellular transformation processes.
CBL is an additional E3 ligase regulating RTK degradation, and it also facilitates ubiquitinylation of wild-type FLT3. 38, 68, 76, 77 The results of our study suggest an alternative pathway, involving UBCH8 and SIAH1, for the degradation of activated wild-type and mutant FLT3. Consistently, CBL functionally interacts with the E2 enzymes UBCH4/5/7, though not with UBCH8, 65, 76 whereas SIAH1 preferentially cooperates with the HDACi-inducible UBCH8. 50, 63 Moreover, several reports show that CBL cannot catalyze ubiquitinylation or degradation of mutant forms of RTKs, such as mutant EGFR, FGFR3, TPR-MET or hybrid receptors of PDGFRa/b. Receptor mislocalization, aberrant phosphorylation and a lack of CBL recruitment account for the reduced efficiency of CBL-mediated degradation of these aberrant proteins. 53, [78] [79] [80] [81] FLT3-ITD has a defect in glycoprotein maturation and gives rise to relatively large amounts of intracellularly retained, albeit active protein.
Our study data indicate that this pool of FLT3-ITD is resistant to CBL-mediated degradation and suggest a model in which SIAH proteins and CBL predominantly target either FLT3-ITD or FLT3 to the UPS. Congruent with our model, CBL has recently been shown to interact predominantly with the mature, cell-surface form of FLT3. 82 Further analyses are required to clarify another possibility, that these RTKs regulate activity and target selectivity of E2 and E3 enzymes by direct phosphorylation.
Although the results of our study imply a critical role of UBCH8 and SIAH proteins mediating FLT3-ITD degradation in cells treated with HDACi, additional mechanisms can contribute to its turnover. Several studies showed that HDACi evoke acetylation of HSP90, which affects co-chaperone and client protein binding. 40, 49, 83 It is possible that UBCH8 mediates receptor degradation downstream of HSP90 acetylation. However, inhibition of HSP90 impairs oncogenic signaling through FLT3-ITD but not its stability per se. 84 In agreement, our gainand loss-of-function approaches indicated that UBCH8 and SIAH1 can evoke FLT3-ITD degradation bypassing the need for HDACi-induced HSP90 hyperacetylation in AML and HEK293T cells. Moreover, depletion of UBCH8 in MV4-11 cells as well as chemical inhibition of the proteasome diminished the basal and the HDACi-accelerated FLT3-ITD turnover.
In addition, our study results collected with the caspase inhibitor Z-VAD-FMK suggested that LBH589-induced caspase activity contributes to the degradation of FLT3-ITD. Caspase-dependent cleavage of HSP90 or its co-chaperone p23 is coupled to endoplasmatic reticulum/oxidative stress and apoptotic cell death. [85] [86] [87] Because caspases can cleave RTKs directly, [88] [89] [90] and HDACi are described as strong inducer of apoptosis in MV4-11 cells, 39,40 FLT3-ITD might also be a direct target of caspases. Apparently, caspase-and proteasomecatalyzed mechanisms cooperatively function on FLT3-ITD in HDACi-treated cells.
It is accepted that HDACi affect protein stability by modulation of the UPS. However, the enzymes catalyzing ubiquitinylation and subsequent degradation under such conditions have only been identified for about a handful of proteins. Even less is known about molecular mechanisms regulating substrate discrimination in this setting. Here, we report for the first time that the E2 ubiquitin conjugase UBCH8 and the E3 ubiquitin ligase SIAH1 phosphorylation dependently catalyze proteasomal degradation of an oncogenic class III RTK.
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